Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Interest & Investment Income of $1.5 million for Q2 2026, down 15.5% year-over-year from $1.8 million in Q2 2025, and down 13.02% quarter-over-quarter from $1.7 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Interest & Investment Income for 8 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 15.5% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $5.9 million (down 49.67% YoY), while the FY2025 annual figure was $7.0 million, down 53.53% from the prior year.
- Interest & Investment Income retreated to $1.5 million in Q2 2026 per PHAT's latest filing, from $1.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.3 million in Q1 2024 and bottomed at $7000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.0 million across 5 years, with a median of $1.6 million in 2026.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 21350.0% — and 2025, when it sank 65.7%.
- Phathom Pharmaceuticals' Interest & Investment Income stood at $1.3 million in 2022, then surged by 160.14% to $3.3 million in 2023, then climbed by 4.84% to $3.5 million in 2024, then tumbled by 65.7% to $1.2 million in 2025, then climbed by 25.42% to $1.5 million in 2026.
- Business Quant data shows PHAT's Interest & Investment Income at $1.5 million in Q2 2026, $1.7 million in Q1 2026, and $1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.51 Mn |
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 2.72 Mn |
| Jun 30, 2023 | 348,000.00 |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.29 Mn |
| Sep 30, 2022 | 726,000.00 |
| Jun 30, 2022 | 112,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 8,000.00 |